8 citations
,
August 2023 in “The Journal of Clinical Endocrinology and Metabolism” This study provided updated international guidelines for assessing and managing polycystic ovary syndrome, emphasizing evidence-based recommendations and acknowledging the low to moderate quality of existing evidence.
254 citations
,
March 2023 in “Diagnostics” This manuscript reviews current diagnostic criteria for polycystic ovary syndrome, emphasizing the need for accurate diagnosis in both clinical and research settings, but it does not provide new clinical findings.
135 citations
,
April 2017 in “Advances in Clinical and Experimental Medicine” This review discusses the causes, clinical implications, and treatment options for polycystic ovary syndrome and reports no new results; the authors highlight both approved and emerging therapies.
767 citations
,
September 2016 in “Human Reproduction” This review analyzes the reported prevalence of polycystic ovary syndrome (PCOS) based on different diagnostic criteria but does not provide new clinical results.
1265 citations
,
October 2013 in “The Journal of Clinical Endocrinology and Metabolism” This guideline from the Endocrine Society recommends using the Rotterdam criteria for diagnosing polycystic ovary syndrome and outlines first-line treatments, emphasizing hormonal contraceptives and lifestyle intervention.
198 citations
,
July 2011 in “Cochrane library” This study found that lifestyle interventions improved body composition, hyperandrogenism, and insulin resistance in women with PCOS, but did not affect glucose tolerance, lipid profiles, or clinical reproductive outcomes.
991 citations
,
January 2011 in “Nature Reviews Endocrinology” This paper reviews the diagnostic criteria, associated morbidities, and possible evolutionary advantages of polycystic ovary syndrome, but does not report any new findings.
4809 citations
,
January 2004 in “Fertility and Sterility” This review discusses polycystic ovary syndrome, emphasizing its broad range of manifestations and associations with risks like type 2 diabetes and cardiovascular events, but reports no new clinical results.